Fortis Healthcare reported a 17.5% year-on-year revenue jump to ₹2,545 crore for the first quarter of fiscal year 2027. While revenue grew, operating margins faced pressure from employee stock option costs and new facility expenses. Brokerage firm Nomura maintained a 'Neutral' rating on the stock, setting a price target of ₹1,030 while expressing caution regarding near-term profitability goals.
Fortis Healthcare posted strong top-line numbers for the first quarter of fiscal year 2027, with revenue growing 17.5% year-on-year to reach ₹2,545 crore. Despite this healthy demand, the company’s operating profit margins felt the heat, coming in at 21.1%. This figure was impacted by roughly ₹31 crore in employee stock option (ESOP) charges. When excluding these costs, the pre-ESOP margin stood at 22.3%.
The decline in margins, compared to some market expectations, was largely influenced by the higher ESOP costs and the initial operational expenses at new hospital sites. As the company scales its operations, these newer facilities often require time before they contribute meaningfully to overall profitability, a common challenge in the hospital sector during phases of rapid expansion.
Expansion and Future Growth Strategy
Looking ahead, the company is actively expanding its capacity to capture future demand. Fortis has announced plans to add 400 new beds over the remaining quarters of fiscal year 2027. Furthermore, the company has approved a capital expenditure of ₹252 crore to build a new proton therapy facility in Gurugram. This investment is a strategic move to enhance its high-end cancer treatment capabilities. Investors will be monitoring how quickly these new projects can turn profitable and contribute to the company's financial health.
Outlook and Sector Challenges
Brokerage firm Nomura has maintained a 'Neutral' stance on the stock but increased its price target to ₹1,030. While acknowledging the growth trajectory, the firm remains cautious about the company’s ability to meet its long-term target of a 25% EBITDA margin by fiscal year 2028. This caution stems from concerns regarding rising employee and doctor costs and the general bargaining power of insurance companies in the healthcare sector.
Additionally, the diagnostics segment remains a key area of focus. While this business continues to grow, it currently trails behind some industry peers in terms of profitability. The company also faces broader sector pressures, including the need to manage operational costs and navigate potential regulatory changes related to hospital pricing.
The key monitorable for investors in the upcoming quarters will be the execution of the planned bed expansion and whether the management can improve margins as these new assets mature. Performance indicators such as the average revenue per occupied bed and the speed at which new facilities achieve stable occupancy will provide clarity on the company's progress toward its margin goals.